# A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone

> **NCT05971940** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 559 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** Orforglipron
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05971940
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-08-09
- **Primary completion:** 2025-04-03
- **Final completion:** 2025-04-03
- **Target enrollment:** 559 (ACTUAL)
- **Last updated:** 2026-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05971940

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05971940, "A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05971940. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*